Focus:
Deals Analysis
-
29 July 2020
Sanofi licenses Kiadis’s modified NK cell therapy for multiple myeloma
Sanofi has licensed Kiadis’s modified K-NK cell therapies to combine with its anti-CD38 antibody Sarclissa in multiple myeloma. How could this combination approach improve treatment outcomes for these blood cancer...
-
24 July 2020
Investing in late-stage companies: Forbion closes Growth Fund at €185m
Forbion has closed its new Growth Opportunities Fund at €185m, but it is hoping to raise a further €65m before the fund is completed this year. This fund will invest...
-
22 July 2020
Exploring the promise of DUBs: Mission teams up with Pfizer
Pfizer Ventures has expanded its relationship with DUB-focused Mission Therapeutics by leading a $15m funding round. The pharma giant’s core company has also signed a scientific partnership to validate promising...
-
22 July 2020
Twist partners with Takeda on antibody drug discovery
Takeda has signed an antibody drug discovery agreement with Twist Bioscience. The pair will use Twist’s synthetic ‘Library of Libraries’ to discover and validate antibody candidates for a range of...
-
20 July 2020
Off-the-shelf NK cell therapies: Artiva closes $78m Series A round
Artiva is working on bringing off-the-shelf NK cell therapies to cancer patients, supported by the manufacturing expertise of GC LabCell. To fund Artiva’s progression of three lead candidates to clinical...
-
14 July 2020
Treating social anxiety disorder: VistaGen and EverInsight collaborate in Asian markets
VistaGen and EverInsight have signed a development and commercialisation agreement for the former’s first-in-class drug for social anxiety disorder. The deal focuses on the Greater China, South Korea and Southeast...
-
13 July 2020
Autobahn Labs: virtual incubator launches with a focus on academia
Autobahn Labs has been launched by Samsara BioCaptial, KCK and Evotec. Purposefully created to invest at earlier stages of development than traditional venture firms, in universities directly and globally because...
-
10 July 2020
Eir Ventures launches to unlock the potential of the Nordics
Supported by three prestigious investment companies and the EU's EIF, Eir Ventures is a Nordic-based venture company with €76m to invest in promising ideas from regional universities and incubators. How...
-
9 July 2020
Gene therapy innovations: Sarepta and Codiak partner on exosome therapies
Sarepta and Codiak are partnering to improve existing gene therapy approaches in neuromuscular diseases through exosome-derived treatments. What are the flaws with AAV approaches and how can exosomes overcome these...
-
6 July 2020
Century acquires Empirica: treating GBM with off-the-shelf cell therapies
By acquiring Empirica and its work on glioblastoma (GBM), Century Therapeutics has taken its first step towards developing off-the-shelf cell therapies for solid tumours. How could this deal improve the...